Talazoparib and enzalutamide improve survival in metastatic castration-resistant prostate cancer

1. Progression-free survival and overall survival were significantly greater in the combination therapy group compared to enzalutamide alone. 2. Anemia and neutropenia were more common with talazoparib compared to enzalutamide alone. Evidence Rating Level: 1 (Excellent) Study Rundown: Metastatic castration-resistant prostate cancer (mCRPC) is difficult to treat, with existing therapies offering limited benefit. Previous studies